Corcept Therapeutics Inc. announced positive results from a clinical study that tested whether CORLUX mitigates the weight gain associated with Risperdal. The results confirmed the results that were previously reported from similar clinical studies of CORLUX, which demonstrated statistically significant mitigation of Zyprexa associated weight gain.
The data demonstrated that adding CORLUX to Risperdal treatment in healthy subjects resulted in a statistically significant reduction in weight gain compared to that seen in subjects receiving Risperdal alone.
Risperdal, a leading antipsychotic for the treatment of schizophrenia and bipolar disorder, is marketed by Johnson & Johnson. CORLUX is Corcept's late-stage GRII receptor antagonist, which the company is also evaluating in ongoing Phase 3 trials for psychotic depression and Cushing's Syndrome.